European Association for Vision and Eye Research – Crete, Oct 5-8, 2011

Ophthalmic surgical clinic “Rascheskoff”, Kazan, RussiaDrs. O.Ziyatdinova, L.Safiullina

Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration

Associated With Retinal Pigment Epithelial Detachment

Financial Disclosure

Dr Olesya Ziyatdinova (the presenter) has no financial interest in the subject matter of this topic

Purpose To evaluate the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.

Materials and methods The study included 15 patients (15 eyes) with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.

5 eyes with foveal involvement

10 eyes without foveal involvement

Duration of disease: from 3 to 12 months

Observation time: 12 months

Number of injections: from 1 to 6 times

Technique Injection of 0,5 mg (0,05ml) of ranibizumab into

vitreous body

Lower quadrant at a distance of 4 mm from limbus, needle 30G

Slow introduction

IOP control and instillation of antibiotics after operation

Technique

Criteria of efficacyVisual acuity (BCVA, UCVA) Ophthalmoscopy

OCT

Results

Average BCVA increased from 20/100 to 20/50 and the average retinal thickness decreased from 367 +/-111 mkm to 281+/- 104 mkm in 8 eyes (53,4%) without foveal involvement.

BCVA remained stable in 5 eyes (33,3%) but there was a decrease only in 2 eyes (13,3%) with foveal involvement.

3 eyes (20%) showed disease stabilization after 1st injection

12 eyes (80%) required re-injection of the ranibizumab for 1-2 months

Results

Before

1 month later

3 months later

OCT dynamics

Conclusions Intravitreal ranibizumab was effective in improving or

stabilizing vision of patients with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.

The functional results were better in eyes without foveal involvement with retinal pigment epithelial detachment.

Visual acuity and OCT data are reliable criteria for evaluating the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.

THANK YOU!

SEEING IS BELIEVING…